InsiderTrades

Form 4 for MNPR Monopar Therapeutics

Accepted 2021-10-01 00:00:00 ET · period of report 2021-09-30 · accession 0001654954-21-010715 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
D 2021-10-01 2021-09-30 MNPR Robinson Chandler CEO, Dir F - Tax $4.87 -1,155 26.8K -4% -$5,625
D 2021-10-01 2021-09-30 MNPR Robinson Chandler CEO, Dir M - OptEx — +3,941 27.9K +16% —
D 2021-10-01 2021-09-30 MNPR Robinson Chandler CEO, Dir M - OptEx $0.00 -3,941 51.2K -7% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2021-09-30 F D 1,155 $4.87 26,758.80 D — —
2 Common Common Stock 2021-09-30 M A 3,941 — 27,913.80 D — — (F1) Represents shares acquired on vesting and settlement of restricted stock units.
3 Derivative Restricted Stock Units 2021-09-30 M D 3,941 $0.00 51,236 D — · — to — 3,941 Common Stock (F1) Represents shares acquired on vesting and settlement of restricted stock units. (F4) On January 26, 2021, the reporting person was granted 63,060 restricted stock units, vesting 6/48ths (7,883 shares) on June 30, 2021, and 3/48ths (3,941 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2024. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement.